Michael D. Burkhart

Array ( [id] => 20622649 [patent_doc_number] => 12590148 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 17/309209 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 31 [patent_no_of_words] => 20420 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18027967 [patent_doc_number] => 11511129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Photosensitive cardiac rhythm modulation systems [patent_app_type] => utility [patent_app_number] => 16/689178 [patent_app_country] => US [patent_app_date] => 2019-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 13090 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16689178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589707 [patent_doc_number] => 20200071388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => Immunoglobulin Variable Region Libraries [patent_app_type] => utility [patent_app_number] => 16/688666 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16053241 [patent_doc_number] => 20200188475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => REAGENTS FOR INDUCING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/683882 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503510 [patent_doc_number] => 20220096612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS FOR INDUCING IMMUNE TOLERANCE [patent_app_type] => utility [patent_app_number] => 17/292923 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533907 [patent_doc_number] => 20220112516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => GENE THERAPY EMPLOYING GENOME EDITING WITH SINGLE AAV VECTOR [patent_app_type] => utility [patent_app_number] => 17/292343 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895237 [patent_doc_number] => 20200147137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/679127 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -89 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314901 [patent_doc_number] => 20210403949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA [patent_app_type] => utility [patent_app_number] => 17/289653 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828555 [patent_doc_number] => 20200129559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => PD-L1 EXPRESSING HEMATOPOIETIC STEM CELLS AND USES [patent_app_type] => utility [patent_app_number] => 16/673283 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16673283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546576 [patent_doc_number] => 20220117917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => PH-ACTIVATED NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/289425 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553593 [patent_doc_number] => 20200061208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO [patent_app_type] => utility [patent_app_number] => 16/666314 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17518 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16666314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867377 [patent_doc_number] => 20220290113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/285440 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761761 [patent_doc_number] => 20220235373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => AGENT THAT ENABLES SIRT7 GENE EXPRESSION AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/610637 [patent_app_country] => US [patent_app_date] => 2019-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15404045 [patent_doc_number] => 20200022344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => HUMANIZED IL-4 AND IL-4Ra ANIMALS [patent_app_type] => utility [patent_app_number] => 16/594537 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267160 [patent_doc_number] => 20200268647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHOD OF ENHANCING DELIVERY OF THERAPEUTIC COMPOUNDS TO THE EYE [patent_app_type] => utility [patent_app_number] => 16/593302 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20356289 [patent_doc_number] => 12472268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Gene therapy for treating propionic acidemia [patent_app_type] => utility [patent_app_number] => 17/278847 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 20 [patent_no_of_words] => 23229 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16086815 [patent_doc_number] => 20200197394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => INHIBITION OF SGK1 IN THE TREATMENT OF HEART CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/573333 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254491 [patent_doc_number] => 20230081530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER USING MRNA THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/275832 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156357 [patent_doc_number] => 20210317408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS [patent_app_type] => utility [patent_app_number] => 17/272631 [patent_app_country] => US [patent_app_date] => 2019-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646799 [patent_doc_number] => 20200085929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS [patent_app_type] => utility [patent_app_number] => 16/543980 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543980 [rel_patent_id] =>[rel_patent_doc_number] =>)